title: Combining cancer immunotherapy and targeted therapy.
abstract: The ability to pharmacologically modulate key signaling pathways that drive tumor growth and progression, but do not negatively impact the function of lymphocytes, provides avenues for rational combinatorial approaches to improve the antitumor activity of tumor immunotherapies. Novel targeted agents can very specifically block oncogenic events in cancer cells, leading to a pro-apoptotic milieu and a potential increase in sensitivity to recognition and attack by cytotoxic T lymphocytes (CTLs). Furthermore, targeted pathway modulation in lymphocytes may change their function and have activating effects in some instances. When tested together with recently developed powerful tumor immunotherapies, such combinations may exploit the highly specific targeting of oncogenes with small molecule inhibitors to lead to high frequency of tumor regressions, and merge this benefit with the durable responses achievable with effective tumor immunotherapies.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, United States. aribas@mednet.ucla.edu
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
mesh_terms: D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
references.citation: Oncoimmunology. 2012 Oct 1;1(7):1189-1190
references.pmid: 23170275
references.citation: Nat Med. 2011 Aug 28;17(9):1094-100
references.pmid: 21873989
references.citation: Nat Med. 2005 Jan;11(1):71-6
references.pmid: 15619634
references.citation: Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200
references.pmid: 20149136
references.citation: Transplant Proc. 2008 Mar;40(2):459-61
references.pmid: 18374101
references.citation: Cancer Res. 2008 Dec 1;68(23):9601-7
references.pmid: 19047136
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):393-403
references.pmid: 23204132
references.citation: Nat Med. 2006 Feb;12(2):214-9
references.pmid: 16444265
references.citation: Clin Cancer Res. 2013 Mar 1;19(5):1225-31
references.pmid: 23307859
references.citation: Cancer Res. 2012 Aug 15;72(16):3928-37
references.pmid: 22693252
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4538-46
references.pmid: 17671140
references.citation: N Engl J Med. 2012 Dec 13;367(24):2316-21
references.pmid: 23134356
references.citation: Cancer Res. 2005 Dec 1;65(23):11136-45
references.pmid: 16322264
references.citation: J Immunol. 2000 Dec 15;165(12):7017-24
references.pmid: 11120829
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1386-94
references.pmid: 22156613
references.citation: Nature. 2009 Jul 2;460(7251):108-12
references.pmid: 19543266
references.citation: Nat Med. 2007 Nov;13(11):1299-307
references.pmid: 17922010
references.citation: Immunity. 2011 Apr 22;34(4):541-53
references.pmid: 21511183
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4141-6
references.pmid: 21368108
references.citation: Int J Cancer. 2008 Jun 1;122(11):2542-53
references.pmid: 18240144
references.citation: J Immunol. 2004 Sep 15;173(6):4171-8
references.pmid: 15356168
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8
references.pmid: 15637150
references.citation: Cancer Cell. 2003 Jul;4(1):13-8
references.pmid: 12892709
references.citation: Cancer Res. 2009 Nov 15;69(22):8693-9
references.pmid: 19861533
references.citation: J Clin Invest. 2013 Mar;123(3):1371-81
references.pmid: 23454771
references.citation: Blood. 2007 Feb 1;109(3):1123-30
references.pmid: 17008546
references.citation: Cancer Res. 2010 Jul 1;70(13):5213-9
references.pmid: 20551059
references.citation: Immunity. 2010 Jan 29;32(1):67-78
references.pmid: 20060330
references.citation: Mol Cancer Ther. 2008 Apr;7(4):740-8
references.pmid: 18413789
references.citation: Mol Cancer Ther. 2004 Apr;3(4):425-35
references.pmid: 15078986
references.citation: Blood. 2000 Dec 1;96(12):3847-56
references.pmid: 11090069
references.citation: Nature. 2010 Mar 18;464(7287):427-30
references.pmid: 20179705
references.citation: Cell. 2010 Jan 22;140(2):209-21
references.pmid: 20141835
references.citation: J Clin Oncol. 2012 Jan 20;30(3):316-21
references.pmid: 22067401
references.citation: Nat Med. 2005 Jan;11(1):77-84
references.pmid: 15619633
references.citation: Cancer Res. 2012 Feb 1;72(3):581-91
references.pmid: 22158905
references.citation: Clin Cancer Res. 2010 Dec 15;16(24):6040-8
references.pmid: 21169256
references.citation: Clin Cancer Res. 2012 Apr 15;18(8):2326-35
references.pmid: 22355009
references.citation: J Invest Dermatol. 2008 Jun;128(6):1506-16
references.pmid: 18185535
references.citation: Biochem Pharmacol. 2003 Oct 15;66(8):1537-45
references.pmid: 14555232
references.citation: Nat Med. 2007 Jan;13(1):84-8
references.pmid: 17159987
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4385-91
references.pmid: 18628452
references.citation: Oncoimmunology. 2012 Aug 1;1(5):609-617
references.pmid: 22934253
references.citation: J Transl Med. 2011 Nov 07;9:192
references.pmid: 22060015
references.citation: Adv Clin Chem. 2010;52:145-67
references.pmid: 21275343
references.citation: J Clin Invest. 2004 Aug;114(3):379-88
references.pmid: 15286804
references.citation: Cancer Immunol Immunother. 2008 May;57(5):647-54
references.pmid: 18046553
references.citation: Cancer Res. 2005 Jul 15;65(14):6321-9
references.pmid: 16024634
references.citation: N Engl J Med. 2012 Jan 19;366(3):207-15
references.pmid: 22256804
references.citation: Nat Rev Clin Oncol. 2011 May 24;8(7):426-33
references.pmid: 21606968
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702
references.pmid: 15738394
references.citation: Blood. 2012 Nov 29;120(23):4533-43
references.pmid: 22936666